While the clinical research community is currently being challenged by the COVID-19 pandemic, adaptive and platform study designs may provide much-needed help for sites.
Strategies for convincing leadership to invest in the tools needed to optimize operations and inform strategic decision-making.
Recent regulations and policies have ushered in the era of mandated single IRB (sIRB) review. Many institutions must now establish policies and processes for working with an external sIRB.
When conducting an investigator-initiated trial, oftentimes, an investigational new drug or investigational device exemption application is necessary. Learn more about IND and IDE reporting.
In this Q&A, Dr. Luke Gelinas answers attendee questions from his webinar “Evaluating Payment to Participate in Research: Ethical and Regulatory Issues.”
In this Part II Q&A, Dr. Suzanne Rose answers additional attendee questions from her webinar “Developing Leaders and Building Successful Careers in your Organization.”
In this Q&A, Dr. Suzanne Rose answers attendee questions from her webinar “Developing Leaders and Building Successful Careers in your Organization.”
Long activations is a familiar concept in the clinical trial landscape. How can your site improve your study activation timelines?